Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether eculizumab is safe and effective in the
treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic
Syndrome (aHUS).